Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease
Background: Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Genetic Engineering and Biotechnology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1687157X24001410 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850244966178095104 |
|---|---|
| author | Maha Abd El Moneem Elfedawy Samia Abd El Sadek Elsebai Hend Mohamed Tawfik Eman Refaat Youness Moushira Zaki |
| author_facet | Maha Abd El Moneem Elfedawy Samia Abd El Sadek Elsebai Hend Mohamed Tawfik Eman Refaat Youness Moushira Zaki |
| author_sort | Maha Abd El Moneem Elfedawy |
| collection | DOAJ |
| description | Background: Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene. Aim of the work: We aimed to explore the efficacy of adropin as a diagnostic candidate biomarker for CVD in patients with CKD. Methods: This is prospective study was carried out on 60 patients (Pt) with CKD and 30 age and sex matched healthy control subjects. CKD Pt were classified according to the history of CVD into two groups: Group A, Pt without history (n = 32) and Group B, Pt with history (n = 28). Serum adropin, lipids and Hs-CRP were measured by ELISA kit. Echocardiography was also investigated. Receiver operator characteristic curve (ROC) was used to determine cut-off points of adropin. Negative predict value (NPV), negative predict value (NPV) and area under curve were detected. Results: There were abnormal ECGs in 78.6 % of CKD patients. Adropin was significantly decreased in Group B than Group A and control group. On the other hand, serum lipids and Hs-CRP were significantly increased in Group B than Group A and control group. ROC analysis revealed that serum adropin could be used to discriminate between patients with and without CVD history at a cutoff level of > 304 with 46.4 % sensitivity and 84.4 % specificity, 74.8 % PPV, 61.2 % NPV and AUC = 0.57. Moreover, between Group A and control at a cutoff level of < 410, with 93.8 % sensitivity, 86.7 % specificity, 87.6 % PPV and 93.3 % NPV and AUC = 0.97 as well as between Group B and control group at a cutoff level of < 416, with 57.1 % sensitivity, 83.3 % specificity, 77.4 % PPV and 66 % NPV and AUC = 0.65. Conclusion: Particularly in CKD patients, adropin may be a useful biomarker for predicting the onset of CVD. Adropin may represent a novel and useful blood marker for assessing systolic function and Spontaneous coronary artery dissection (SCAD). |
| format | Article |
| id | doaj-art-d5dace4ec0674bc28dc93d0865b5e97b |
| institution | OA Journals |
| issn | 1687-157X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Genetic Engineering and Biotechnology |
| spelling | doaj-art-d5dace4ec0674bc28dc93d0865b5e97b2025-08-20T01:59:35ZengElsevierJournal of Genetic Engineering and Biotechnology1687-157X2024-12-0122410043810.1016/j.jgeb.2024.100438Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney diseaseMaha Abd El Moneem Elfedawy0Samia Abd El Sadek Elsebai1Hend Mohamed Tawfik2Eman Refaat Youness3Moushira Zaki4Department of Internal Medicine, Faculty of Medicine, Al-Azher University (for girls), EgyptDepartment of Internal Medicine, Faculty of Medicine, Al-Azher University (for girls), EgyptDepartment of Internal Medicine, Faculty of Medicine, Al-Azher University (for girls), EgyptMedical Biochemistry Department, Medical Research and Clinical Studies Institute – National Research Centre Cairo, EgyptBiological Anthropology Department, Medical Research and Clinical Studies Institute–National Research Centre Cairo, Egypt; Corresponding author.Background: Chronic kidney disease (CKD) is a chief worldwide health concern that has a substantial financial impact on health systems, high rates of mortality and morbidity as well as cardiovascular disease (CVD) is a major cause of mortality in this population. Adropin is a unique hormone encoded by the energy homeostasis-associated (Enho) gene. Aim of the work: We aimed to explore the efficacy of adropin as a diagnostic candidate biomarker for CVD in patients with CKD. Methods: This is prospective study was carried out on 60 patients (Pt) with CKD and 30 age and sex matched healthy control subjects. CKD Pt were classified according to the history of CVD into two groups: Group A, Pt without history (n = 32) and Group B, Pt with history (n = 28). Serum adropin, lipids and Hs-CRP were measured by ELISA kit. Echocardiography was also investigated. Receiver operator characteristic curve (ROC) was used to determine cut-off points of adropin. Negative predict value (NPV), negative predict value (NPV) and area under curve were detected. Results: There were abnormal ECGs in 78.6 % of CKD patients. Adropin was significantly decreased in Group B than Group A and control group. On the other hand, serum lipids and Hs-CRP were significantly increased in Group B than Group A and control group. ROC analysis revealed that serum adropin could be used to discriminate between patients with and without CVD history at a cutoff level of > 304 with 46.4 % sensitivity and 84.4 % specificity, 74.8 % PPV, 61.2 % NPV and AUC = 0.57. Moreover, between Group A and control at a cutoff level of < 410, with 93.8 % sensitivity, 86.7 % specificity, 87.6 % PPV and 93.3 % NPV and AUC = 0.97 as well as between Group B and control group at a cutoff level of < 416, with 57.1 % sensitivity, 83.3 % specificity, 77.4 % PPV and 66 % NPV and AUC = 0.65. Conclusion: Particularly in CKD patients, adropin may be a useful biomarker for predicting the onset of CVD. Adropin may represent a novel and useful blood marker for assessing systolic function and Spontaneous coronary artery dissection (SCAD).http://www.sciencedirect.com/science/article/pii/S1687157X24001410AdropinCardiovascular diseaseChronic kidney diseasePredictive valuesSensitivitySpecificity |
| spellingShingle | Maha Abd El Moneem Elfedawy Samia Abd El Sadek Elsebai Hend Mohamed Tawfik Eman Refaat Youness Moushira Zaki Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease Journal of Genetic Engineering and Biotechnology Adropin Cardiovascular disease Chronic kidney disease Predictive values Sensitivity Specificity |
| title | Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| title_full | Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| title_fullStr | Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| title_full_unstemmed | Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| title_short | Adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| title_sort | adropin a candidate diagnostic biomarker for cardiovascular disease in patients with chronic kidney disease |
| topic | Adropin Cardiovascular disease Chronic kidney disease Predictive values Sensitivity Specificity |
| url | http://www.sciencedirect.com/science/article/pii/S1687157X24001410 |
| work_keys_str_mv | AT mahaabdelmoneemelfedawy adropinacandidatediagnosticbiomarkerforcardiovasculardiseaseinpatientswithchronickidneydisease AT samiaabdelsadekelsebai adropinacandidatediagnosticbiomarkerforcardiovasculardiseaseinpatientswithchronickidneydisease AT hendmohamedtawfik adropinacandidatediagnosticbiomarkerforcardiovasculardiseaseinpatientswithchronickidneydisease AT emanrefaatyouness adropinacandidatediagnosticbiomarkerforcardiovasculardiseaseinpatientswithchronickidneydisease AT moushirazaki adropinacandidatediagnosticbiomarkerforcardiovasculardiseaseinpatientswithchronickidneydisease |